Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis

被引:94
|
作者
Njock, Makon-Sebastien [1 ]
Guiot, Julien [2 ,3 ]
Henket, Monique A. [2 ,3 ]
Nivelles, Olivier [1 ]
Thiry, Marc [4 ]
Dequiedt, Franck [5 ]
Corhay, Jean-Louis [2 ,3 ]
Louis, Renaud E. [2 ,3 ]
Struman, Ingrid [1 ]
机构
[1] Univ Liege, Lab Mol Angiogenesis, GIGA R, Liege, Belgium
[2] CHU Liege, Pneumol Dept, Liege, Belgium
[3] Univ Liege, Lab Pneumol, GIGA I3, Liege, Belgium
[4] Univ Liege, Lab Biol Cellulaire & Tissulaire, GIGA R, Liege, Belgium
[5] Univ Liege, Lab Signalisat & Interact Prot, GIGA R, Liege, Belgium
关键词
idiopathic pulmonary fibrosis; interstitial fibrosis;
D O I
10.1136/thoraxjnl-2018-211897
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease of unknown aetiology which leads rapidly to death. As diagnosis of IPF is complex, we aimed to characterise microRNA (miRNA) content of exosomes from sputum of patients with IPF. Using miRNA quantitative PCR array, we found a substantial dysregulation of sputum exosomal miRNA levels between patients with IPF and healthy subjects and identified a unique signature of three miRNAs. Interestingly, we found a negative correlation between miR-142-3p and diffusing capacity of the lungs for carbon monoxide/alveolar volume. This is the first characterisation of miRNA content of sputum-derived exosomes in IPF that identified promising biomarkers for diagnosis and disease severity.
引用
收藏
页码:309 / 312
页数:4
相关论文
共 50 条
  • [1] Sputum eosinophilia in idiopathic pulmonary fibrosis
    Birring, SS
    Parker, D
    McKenna, S
    Hargadon, B
    Brightling, CE
    Pavord, ID
    Bradding, P
    INFLAMMATION RESEARCH, 2005, 54 (02) : 51 - 56
  • [2] Sputum eosinophilia in idiopathic pulmonary fibrosis
    S. S. Birring
    D. Parker
    S. McKenna
    B. Hargadon
    C. E. Brightling
    I. D. Pavord
    P. Bradding
    Inflammation Research, 2005, 54 : 51 - 56
  • [3] Blood Biomarkers in Idiopathic Pulmonary Fibrosis
    Guiot, Julien
    Moermans, Catherine
    Henket, Monique
    Corhay, Jean-Louis
    Louis, Renaud
    LUNG, 2017, 195 (03) : 273 - 280
  • [4] Serum biomarkers in idiopathic pulmonary fibrosis
    van den Blink, Bernt
    Wijsenbeek, Marlies S.
    Hoogsteden, Henk C.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (06) : 515 - 520
  • [5] Blood Biomarkers in Idiopathic Pulmonary Fibrosis
    Julien Guiot
    Catherine Moermans
    Monique Henket
    Jean-Louis Corhay
    Renaud Louis
    Lung, 2017, 195 : 273 - 280
  • [6] Idiopathic pulmonary fibrosis misdiagnosed as sputum-negative pulmonary tuberculosis
    Isah, Muhammad Danasabe
    Abbas, Aminu
    Abba, Abdullahi A.
    Umar, Mohammed
    Annals of African Medicine, 2016, 15 (04) : 204 - 206
  • [7] Biomarkers in idiopathic pulmonary fibrosis: Are we there yet?
    Prasad, Jyotika D.
    RESPIROLOGY, 2020, 25 (07) : 674 - 675
  • [8] Potential new biomarkers for idiopathic pulmonary fibrosis
    Milenkovic, Marina Roksandic
    Stevuljevic, Jelena Kotur
    Ceriman, Vesna
    Milenkovic, Vladislav
    Jovanovic, Dragana
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [9] Biomarkers in the Evaluation and Management of Idiopathic Pulmonary Fibrosis
    Tzouvelekis, Argyris
    Herazo-Maya, Jose
    Sakamoto, Koji
    Bouros, Demosthenes
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (14) : 1587 - 1598
  • [10] Promising advances in treatments for the management of idiopathic pulmonary fibrosis
    Sofia, Carmelo
    Comes, Alessia
    Sgalla, Giacomo
    Richeldi, Luca
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (06) : 717 - 725